Evidence map›Paper›PMID 39921516›Full record

ArticleJournal of the American Heart Association2025

Melanocortin 1 Receptor Regulates Pathological and Physiological Cardiac Remodeling.

Anni Suominen, Aino Suni, Saku Ruohonen, Zoltán Szabó, Lotta Pohjolainen, Minying Cai, Eriika Savontaus, Virpi Talman, Risto Kerkelä, Petteri Rinne

Abstract read
In one paragraph

Article in Journal of the American Heart Association, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Article
  2. Article
  3. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Anni SuominenResearch Centre for Integrative Physiology & Pharmacology, Institute of Biomedicine University of Turku Finland.
Aino SuniResearch Centre for Integrative Physiology & Pharmacology, Institute of Biomedicine University of Turku Finland.
Saku RuohonenResearch Centre for Integrative Physiology & Pharmacology, Institute of Biomedicine University of Turku Finland.
Zoltán SzabóResearch Unit of Biomedicine and Internal Medicine, Department of Pharmacology and Toxicology University of Oulu Finland.ORCID 0000-0003-0778-1113
Lotta PohjolainenDrug Research Program and Division of Pharmacology and Pharmacotherapy, Faculty of Pharmacy University of Helsinki Finland.ORCID 0000-0001-8852-6709
Minying CaiDepartment of Chemistry and Biochemistry University of Arizona Tucson AZ USA.ORCID 0000-0001-9504-2091
Eriika SavontausResearch Centre for Integrative Physiology & Pharmacology, Institute of Biomedicine University of Turku Finland.ORCID 0000-0003-3421-0367
Virpi TalmanResearch Centre for Integrative Physiology & Pharmacology, Institute of Biomedicine University of Turku Finland.ORCID 0000-0002-2702-6505
Risto KerkeläResearch Unit of Biomedicine and Internal Medicine, Department of Pharmacology and Toxicology University of Oulu Finland.ORCID 0000-0001-7194-9326
Petteri RinneResearch Centre for Integrative Physiology & Pharmacology, Institute of Biomedicine University of Turku Finland.ORCID 0000-0001-6916-8627

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundThe melanocortin 1 receptor (MC1R) is abundantly expressed in the skin and leukocytes, where it regulates skin pigmentation and inflammatory responses. Recently, MC1R was also found in the heart, but its functional role has remained unknown. We aimed to investigate whether MC1R is involved in the regulation of pathological or physiological cardiac remodeling. METHODS AND

resultsRecessive yellow mice, as a model of global MC1R deficiency, and cardiomyocyte-specific MC1R knockout mice were subjected to transverse aortic constriction or voluntary wheel running to induce pathological or physiological cardiac hypertrophy, respectively. Mice were phenotyped for cardiac structure and function by echocardiography, histology, and quantitative PCR analysis. H9c2 cells and neonatal mouse ventricular cardiac myocytes were used as in vitro models to investigate the effects of pharmacological MC1R activation on hypertrophy-related responses. We found that the expression of MC1R progressively declines in the failing mouse heart. MC1R recessive yellow mice showed blunted hypertrophic response to transverse aortic constriction-induced pressure overload and exercise training. This phenotype was recapitulated in MC1R knockout mice, demonstrating that MC1R deficiency specifically in cardiomyocytes is responsible for the antihypertrophic effect. However, MC1R knockout mice subjected to pressure overload showed left ventricular dilatation that was associated with reduced ejection fraction and changes in left ventricular diastolic function. At the molecular level, the mRNA expression of myosin heavy chain β was upregulated in the hearts of MC1R knockout mice. In contrast, selective activation of MC1R promoted hypertrophic responses in cultured cardiomyocytes.

conclusionsCardiomyocyte-specific MC1R deficiency attenuates physiological and pathological cardiac hypertrophy in mice, while pharmacological activation of MC1R promotes cardiomyocyte hypertrophy.

Indexed as

CardiomegalyHeart FailureHypertrophy, Left VentricularMyocytes, CardiacReceptor, Melanocortin, Type 1Ventricular RemodelingAnimalsDisease Models, AnimalMaleMiceMice, Inbred C57BLMice, KnockoutPhenotypeRatsVentricular Function, LeftReceptor, Melanocortin, Type 1cardiac hypertrophycardiomyocyteheart failuremelanocortin 1 receptor

Identifiers

PMID39921516
PMCPMC12074753

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.